{"classes":[{"categories":[{"measurements":[{"comment":"Some participants continued to have a sustained response at the time of study completion.","groupId":"OG000","lowerLimit":"227","upperLimit":"NA","value":"308"},{"comment":"Some participants continued to have a sustained response at the time of study completion.","groupId":"OG001","lowerLimit":"282","upperLimit":"NA","value":"803"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"5"}],"units":"Participants"}],"description":"Descriptively presented for each treatment group and no formal statistical comparison will be made between treatment arms","dispersionType":"95% Confidence Interval","groups":[{"description":"Subjects on the BiRD arm will receive clarithromycin, lenalidomide, and dexamethasone in 28-day cycles.\n\nClarithromycin: 500mg PO twice daily on days 1-28 for a 28-day cycle.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG000","title":"BiRD Treatment Regimen"},{"description":"Subjects on the Rd arm will receive lenalidomide and dexamethasone in 28-day cycles.\n\nLenalidomide: 25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle\n\nDexamethasone: 20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.","id":"OG001","title":"Rd Treatment Regimen"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"up to 3 years","title":"Number of Days for Duration of Response","type":"SECONDARY","unitOfMeasure":"days"}